PAVmed Announces Reverse Stock Split
MWN-AI** Summary
PAVmed Inc. (NASDAQ: PAVM), a diversified medical technology company, announced a 1-for-30 reverse stock split of its common stock, set to take effect on January 2, 2026. This strategic move is aimed at ensuring compliance with Nasdaq's $1.00 minimum bid price requirement for listing. Following approval by shareholders during a special meeting on December 5, 2025, the board officially sanctioned the specific split ratio on December 8, 2025.
Post-split, the number of authorized shares will drop from 250 million to 25 million. Accordingly, shares available under the company's equity incentive and employee stock purchase plans will also be proportionately reduced. Furthermore, the exercise prices and the number of shares for outstanding stock options and convertible securities will be adjusted to reflect the new share structure. Importantly, fractional shares arising from the reverse split will not be issued; instead, these will be rounded up to the nearest whole share for affected stockholders.
PAVmed operates in the medical device, diagnostics, and digital health sectors, with subsidiaries like Lucid Diagnostics Inc. and Veris Health Inc. Lucid focuses on cancer prevention, notably with its EsoGuard® and EsoCheck® technologies, while Veris Health advances personalized cancer care through innovative monitoring solutions.
The new CUSIP number for the common stock will be 70387R 502 following the split. As PAVmed navigates market dynamics, the reverse stock split could play a crucial role in stabilizing share prices and enhancing investor confidence, although potential risks remain, including market volatility and the challenges inherent in R&D and regulatory approvals. For further information, stakeholders are referred to PAVmed's official channels.
MWN-AI** Analysis
In recent trading news, PAVmed Inc. (NASDAQ: PAVM) has announced a 1-for-30 reverse stock split effective January 2, 2026. This strategic move aims to comply with the Nasdaq $1.00 minimum bid price requirement, ensuring the stock’s continued listing on this prominent exchange.
Reverse stock splits are often employed by companies facing low share prices and can signal a commitment to long-term viability. However, they can also raise concerns among investors regarding the company’s financial health. For PAVmed, this drastic measure may initially induce volatility as the market adjusts to the altered share count and price dynamics.
From a market perspective, this split drastically reduces the share count from 250 million to 25 million shares, which can enhance the perceived value of each share. Investors may view this as a step toward restructuring and could potentially interpret it as a positive indication of management's intent to strengthen the company’s market positioning.
However, the underlying fundamentals remain critical. Investors must closely monitor PAVmed’s operational performance, particularly the market reception of its products, such as the EsoGuard® and EsoCheck® devices, which are positioned within the growing field of cancer diagnostics. Furthermore, PAVmed’s digital health initiatives through its subsidiary, Veris Health, warrant scrutiny as they evolve.
In conclusion, while the reverse stock split offers a pathway to compliance and perceived stabilization, potential investors should weigh this against the inherent risks. It’s advisable to conduct deeper analysis into PAVmed’s financial statements and market strategies while considering the broader context of the healthcare technology sector, characterized by high innovation but equally high competition and regulatory hurdles. Caution and thorough analysis are recommended before making investment decisions in a newly modified share structure.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
NEW YORK, Dec. 30, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced it will conduct a 1-for-30 reverse stock split of its common stock (the "Common Stock"). The reverse stock split will become effective on January 2, 2026, at 12:01 a.m. Eastern Time. The Company's Common Stock will continue to trade on the Nasdaq Capital Market ("Nasdaq") under the symbol "PAVM" and will begin trading on a split-adjusted basis at the opening of the market on January 2, 2026. The reverse stock split is intended to bring the Company into compliance with the $1.00 minimum bid price requirement for maintaining the listing of its Common Stock on Nasdaq.
The reverse stock split was approved by the Company's stockholders at the Company's special meeting of stockholders held on December 5, 2025, with the specific ratio to be determined at the discretion of the Company's board of directors within approved parameters. The ratio of 1-for-30 was approved by the board on December 8, 2025. As of the effective time of the reverse stock split, the authorized shares of Common Stock will be reduced from 250,000,000 to 25,000,000 (which reduction was approved, subject to completion of the reverse stock split, by the Company's stockholders at the same special meeting).
As a result of the reverse stock split, the number of shares of Common Stock available for issuance under the Company's equity incentive plan and employee stock purchase plan immediately prior to the reverse stock split will be proportionately reduced. In addition, the exercise prices of and number of shares subject to the Company's outstanding stock options, and the conversion prices of the Company's outstanding convertible securities, including its convertible debt and preferred stock, will likewise be proportionately adjusted in accordance with their respective terms.
No fractional shares of Common Stock will be issued in connection with the reverse stock split. Stockholders that would hold a fractional share of Common Stock as a result of the reverse stock split will have such fractional shares of Common Stock rounded up to the nearest whole share of Common Stock.
The new CUSIP number for the Common Stock following the reverse stock split is 70387R 502.
About PAVmed and its Subsidiaries
PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its subsidiary, Lucid Diagnostics Inc. (NASDAQ: LUCD), is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer to mitigate the risks of esophageal cancer deaths. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices. Veris is concurrently developing an implantable physiological monitor, designed to be implanted alongside a chemotherapy port, which will interface with the Veris Cancer Care Platform.
For more and for more information about PAVmed, please visit pavmed.com.
For more information about Lucid Diagnostics, please visit luciddx.com.
For more information about Veris Health, please visit verishealth.com.
Forward-Looking Statements
This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of PAVmed's and Lucid's management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of PAVmed's and Lucid's common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance PAVmed's and Lucid's products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from PAVmed's and Lucid's clinical and preclinical studies; whether and when PAVmed's and Lucid's products are cleared by regulatory authorities; market acceptance of PAVmed's and Lucid's products once cleared and commercialized; PAVmed's and Lucid's ability to raise additional funding as needed; and other competitive developments. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect PAVmed's and Lucid's future operations, see Part I, Item 1A, "Risk Factors," in PAVmed's and Lucid's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by PAVmed or Lucid after its most recent Annual Report. PAVmed and Lucid disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.
SOURCE PAVmed Inc.
FAQ**
How will the 1-for-30 reverse stock split impact the market perception of PAVmed and its subsidiary, Lucid Diagnostics Inc. (LUCD), in terms of investor confidence and stock liquidity?
What specific financial metrics or indicators prompted the board of PAVmed to approve the reverse stock split, and how might this affect its subsidiary, Lucid Diagnostics Inc. (LUCD)?
With the reduced number of authorized shares following the reverse stock split, how does PAVmed plan to maintain employee incentives, particularly in relation to Lucid Diagnostics Inc. (LUCD)?
How does PAVmed anticipate the reverse stock split will influence the strategic growth opportunities for its subsidiaries, such as Lucid Diagnostics Inc. (LUCD), in the competitive medical technology market?
**MWN-AI FAQ is based on asking OpenAI questions about Lucid Diagnostics Inc. (NASDAQ: LUCD).
NASDAQ: LUCD
LUCD Trading
-1.38% G/L:
$1.43 Last:
325,849 Volume:
$1.40 Open:
